" class="no-js "lang="en-US"> Amira Barkal - Medtech Alert
Tuesday, April 22, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Amira Barkal

Amira Barkal

About Amira Barkal

Physician-scientist and resident physician in Internal Medicine at Brigham & Women’s Hospital at Harvard Medical School. Graduate of the Stanford Medical Scientist Training Program. Completed my PhD thesis with Irv Weissman in the Institute of Stem Cell Biology & Regenerative Medicine. Interested in oncology, cancer immunotherapy, and translational medicine.

Principal Founder of Pheast Therapeutics, a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer.

Related Story

Diseases

 Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer | Pharmtech Focus

Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer

April 27 2022

Pheast Therapeutics, a company developing novel checkpoint therapies to fight cancer, today announced it has […]